We are live on ! Find out more
INSY

Insys Therapeutics, Inc.
INSY

Delisted

INSY was delisted on the 18th of June, 2019.

16 hedge funds and large institutions have $52K invested in Insys Therapeutics, Inc. in 2019 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 82 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

84% less funds holding

Funds holding: 9816 (-82)

95% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 82

100% less capital invested

Capital invested by funds: $51.6M → $52K (-$51.6M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $1K

Holders
16
Holders Change
-82
Holders Change %
-83.67%
% of All Funds
0.35%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
1
Reduced
1
Closed
82
Calls
Puts
$1K
Net Calls
-$1K
Net Calls Change
+$516K

INSY Hedge Fund Activity: Q2 2019 in Review

16 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q2 2019, worth a combined $52K — down 100% from $51.6M a quarter earlier.

Sellers outnumbered buyers: 82 funds closed out of INSY and 4 opened new positions — a net loss of 78 holders — while 1 trimmed existing stakes and 1 added.

The largest buyer was KBC Group, opening a new position worth an estimated $142K. The largest seller was Vanguard Group, exiting entirely with an estimated $12.8M sold.

  • 16 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q2 2019, down from 98 in Q1 2019.
  • Funds reported $52K of Insys Therapeutics, Inc. stock for Q2 2019, down 100% quarter-over-quarter.
  • 4 funds opened new Insys Therapeutics, Inc. positions in Q2 2019 and 82 closed out, a net change of -78 holders.
  • The largest Insys Therapeutics, Inc. buyer in Q2 2019 was KBC Group, an estimated $142K added.
  • The largest Insys Therapeutics, Inc. seller in Q2 2019 was Vanguard Group, an estimated $12.8M sold.

Based on aggregated 13F filings for Q2 2019.